Clinical trials
Unresectable Pancreatic Cancer clinical trials
Below are recruiting unresectable pancreatic cancer clinical trials, each written for real people, not researchers. We’re tracking 167 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06043921Recruiting
Personalized blood test for pancreatic cancer
This study uses a personalized blood test to look for tiny pieces of tumor DNA in people with pancreatic cancer. It helps doctors understand how the cancer changes during treatment.
KashiwaAges 20 years+ - NCT06690528RecruitingPhase 2
Surgery vs. palliative care for pancreatic cancer with limited liver spread
This trial compares surgery to remove the primary tumor and up to 3 liver spots against standard palliative care for people with pancreatic cancer that has spread only to the liver (up to 3 spots). It is for those whose cancer has not grown after initial chemotherapy and who are healthy enough for surgery.
Padova, ItalyAges 18–75 - NCT07066098RecruitingPhase 3
New drug IBI343 for advanced pancreatic cancer with CLDN18.2 protein
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07033689RecruitingEarly Phase 1
Testing Suizenji for newly diagnosed pancreatic cancer
This trial tests a new ultrasound treatment called Suizenji for people with pancreatic cancer that cannot be removed by surgery. The goal is to see if it can safely target the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT06403735RecruitingPhase 1
Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Guangzhou, GuangdongAges 18 years+ - NCT04421820RecruitingPhase 1/Phase 2
BOLD-100 with chemo for advanced gut cancer
This Phase 1/2 study tests whether BOLD-100, given with the standard chemo combination FOLFOX, can help people with advanced gastrointestinal cancers. It’s especially focused on specific tumor features (including BRAF status) and checks safety, dosing, and early signs of effectiveness.
Santa Monica, CaliforniaAges 18 years+ - NCT03190941RecruitingPhase 1/Phase 2
T-cell therapy for HLA-A11:01 and KRAS G12V tumors
This trial tests a custom immune-cell treatment made from your blood that targets the KRAS G12V change in certain cancers. It is for people with advanced cancer who have already tried standard treatments, and it may help your immune system recognize and attack tumor cells.
Bethesda, MarylandAges 18–72 - NCT06533332RecruitingPhase 1
Testing ERX-315 for advanced solid tumors
This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Ryde, New South WalesAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06898385RecruitingPhase 1
IX001 TCR-T Cells for Advanced Pancreatic Cancer with KRAS G12V
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT07636382Recruiting
Radiation to relieve cancer-related belly pain from celiac plexus involvement
This trial tests a focused radiation treatment called stereotactic body radiotherapy (SBRT) to target pain from cancer affecting the celiac plexus—a bundle of nerves in the upper abdomen. The goal is to relieve severe, persistent pain without surgery.
Toronto, OntarioAges 18 years+ - NCT07241676Enrolling by invitation
Pancreatic cancer surgery and early recurrence study
This study looks at patients who had surgery to remove pancreatic cancer to understand what factors might lead to the cancer coming back early. If you have had surgery for pancreatic cancer and are interested in helping researchers learn more, this may be a fit.
Padova, PDAges 18 years+ - NCT07283705RecruitingPhase 2
Study of BMS-986504 for MTAP-deleted pancreatic cancer
This trial tests a new drug, BMS-986504, in people with pancreatic cancer that has a specific genetic change called MTAP deletion. The study aims to see if this drug can help shrink or control the tumor.
Houston, TexasAges 18 years+ - NCT06282809Recruiting
Sound wave therapy for pancreatic cancer
This trial tests a new device that uses sound waves (histotripsy) to break apart pancreatic tumors without surgery. It is for people with advanced pancreatic cancer that cannot be removed and who have already had chemotherapy. The goal is to see if this treatment can help control the tumor.
BarcelonaAges 18 years+ - NCT05438459RecruitingPhase 1/Phase 2
GAIA-102 for advanced stomach or pancreatic cancer with ascites
This trial tests a new drug, GAIA-102, given directly into the abdomen to treat advanced stomach or pancreatic cancer that has spread to the belly lining and causes fluid buildup (malignant ascites). The goal is to see if it can slow the cancer or improve symptoms.
Fukuoka, FukuokaAges 20 years+ - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT06008288RecruitingPhase 2
JAB-21822 for advanced pancreatic or other solid tumors with KRAS G12C
This study tests an experimental pill called JAB-21822 that targets a specific gene change (KRAS G12C) in advanced pancreatic cancer or other solid tumors. It's for people who have already tried standard chemotherapy and whose cancer has gotten worse or who couldn't handle the side effects.
Hefei, AnhuiAges 18 years+ - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+
Hear when a new Unresectable Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable pancreatic cancer?
- Yes. Clin2 currently lists 167 recruiting unresectable pancreatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable pancreatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable pancreatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.